Guggenheim raised the firm’s price target on Zenas BioPharma (ZBIO) to $55 from $45 and keeps a Buy rating on the shares. The firm updated its model to account for “several notable pipeline updates” that came with the company’s Q4 report, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Balanced Near‑Term Outlook for Zenas BioPharma: Promising Obexelimab Pipeline and Strengthened Liquidity Offset by Commercial and Leverage Uncertainties
- Zenas BioPharma price target raised to $21 from $19 at Morgan Stanley
- Zenas BioPharma: De‑Risked Autoimmune Late‑Stage Assets and Strong Balance Sheet Underpin Buy Rating and $44 Target
- Zenas BioPharma price target lowered to $41 from $43 at Citi
- IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma